Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

What Clinical Trials Have Been Conducted on Cannabis for EDS? 

Posted
Updated
ByMy Patient Advice
Author: Dr. Clarissa Morton, PharmD

Interest in cannabis trials EDS  is growing as patients seek safer alternatives to manage chronic pain and other symptoms. While formal clinical trials remain limited, a mix of real-world data and early registries are shedding light on the potential effectiveness and safety of cannabis for Ehlers-Danlos Syndrome (EDS clinical research). 

Can I treat my condition with Medical Cannabis?

Key Findings from Emerging Studies and Registries 

  • Project Twenty21 (UK observational study): 
    An ongoing observational trial under Drug Science’s Project Twenty21 has gathered data from thousands of patients, including those with EDS, to assess the safety and efficacy of medical cannabis. As one of the largest UK trials to date on medical cannabis, it offers early insight into how cannabis might benefit EDS patients. 
  • Case Report (London, 2021): 
    A documented case from University College London highlighted a young woman with hypermobile EDS who experienced significant reductions in chronic pain and was able to discontinue high-dose opioid treatment after beginning cannabis therapy. 
  • UK Medical Cannabis Registry Analysis (2025): 
    Recent data from a large UK registry study involving patients with hypermobile EDS reported sustained improvements in pain scores, sleep quality, and emotional well-being after long-term use of cannabis-based medicinal products, with no serious safety concerns reported. 

What This Means for Future Cannabis Trials EDS 

While randomised controlled trials are still lacking, observational research and real-world data are beginning to support cannabis effectiveness for managing EDS symptoms. Continued EDS clinical research is essential to validate these findings and develop evidence-based guidelines for safe and effective use. 

Visit providers like LeafEase for personalised consultations to explore how this evolving research might apply to your treatment plan. 

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to medical cannabis and Ehlers-Danlos Syndrome. 

Dr. Clarissa Morton, PharmD
Author

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Categories